Document is current
Any future updates will be listed below
-
Authors
Chen, Xiaofeng
Wu, Xiaofeng
Wu, Hao
Gu, Yanhong
Shao, Yang
Shao, Qianwen
Zhu, Feipeng
Li, Xiao
Qian, Xiaofeng
Hu, Jun
Zhao, Fengjiao
Mao, Weidong
Sun, Jing
Wang, Jian
Han, Gaohua
Li, Changxian
Xia, Yongxiang
Seesaha, Poshita Kumari
Zhu, Dongqin
Li, Huajun
Zhang, Junling
Wang, Guoqiang
Wang, Xuehao
Li, Xiangcheng
Shu, Yongqian https://orcid.org/0000-0003-2103-0877
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03486678 at ClinicalTrials.govnct03111732 at ClinicalTrials.govDocuments that mention this clinical trial
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
https://doi.org/10.1136/jitc-2021-003214
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
https://doi.org/10.1136/jitc-2020-001240
nct04003636 at ClinicalTrials.govDocuments that mention this clinical trial
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
https://doi.org/10.1136/jitc-2020-001240
nct03101566 at ClinicalTrials.govDocuments that mention this clinical trial
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404
Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC).
https://doi.org/10.1200/jco.2024.42.16_suppl.4093
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
https://doi.org/10.1136/jitc-2020-001240
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: perspectives from US and Chinese payers (Post-results)
https://doi.org/10.1136/bmjopen-2024-094047
Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC).
https://doi.org/10.1200/jco.2023.41.16_suppl.4003
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
Documents that mention this clinical trial
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
https://doi.org/10.1136/jitc-2020-001240
-
Funding
Funding for this research was provided by:
the Advanced Health Talent of Six-One Project of Jiangsu Province (LGY2017069)
Joint Research Project by Southeast University and Nanjing Medical University (3207027381)
National Natural Science Foundation of China (81472306)
Key research and development program of Jiangsu Province (BE2016789)
Jiangsu province 333 high level Talents Project
Innovation Funds From Chinese Society Of Clinical Oncology Youth Committee (Y-young2019-060)
- License Information
